Biological bases of anxiety

Neuroscience and Biobehavioral Reviews

Volumn 22, Issue 5, 1998, Pages 623-633

  Clement, Yan ^a   Chapouthier, Georges ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Anxiety; Brain regions; Genetic factors; Neurotransmitter systems

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; CHOLECYSTOKININ; FLUMAZENIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; PENTETRAZOLE; PICROTOXIN; SEROTONIN; SEROTONIN RECEPTOR; STRYCHNINE;

ADRENERGIC SYSTEM; AGGRESSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; CONFLICT; GABAERGIC SYSTEM; GENETICS; HUMAN; IMPULSIVENESS; LEARNING; LIMBIC SYSTEM; MEMORY; MOUSE; NEUROTRANSMISSION; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; RODENT; SEIZURE; SEROTONINERGIC SYSTEM;

EID: 0031776779     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(97)00058-4     Document Type: Article

References (178)

1. Abadie, P., Bisserbe, J. C., Boulenger, J. P., Travere, J. M., Barre, L., Petit, M. C. et al., New concepts in anxiety. In M. Briley and S. E. File, ed. The MacMillan Press, London, 1991, pp. 203-210.
2. Alho H., Costa E., Ferrero P., Fujimoto M., Cosenza-Murphy D., Guidotti A. Diazepam-binding inhibitor: A neuropeptide located in selected neuronal populations of rat brain. Science. 299:1985;179-182.
3. Andrews N., Hogg S., Gonzales L. E., File S. E. 5-HT1A receptors in the median raphe nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviors respectively. Eur. J. Pharmacol. 264:1994;259-264.
4. Anglade, F., Bizot, J. C., Dodd, R. H., Baudoin, C., Chapouthier, G., Opposite effects of cholinergic agents and benzodiazepine receptor ligands in a passive avoidance learning task in rats. Neurosci. Lett. 182:1994;247-250.
5. Angus W. R., Romney D. M. Three effects of diazepam on patients memory. J. Clin. Psychopharmacol. 4:1984;203-206.
6. Archer J. Tests for emotionality in rats and mice, a review. Anim. Behav. 21:1973;205-235.
7. Artaiz I., Rmero G., Zazpe A., Monge A., Caldero J. M., Roca J.et al. The pharmacology of VA21B7: An atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models. Psychopharmacol. (Berlin). 117:1995;137-148.
8. Babbini, M., Gaiardi, M., Bartoletti, M., Benzodiazepines effects upon Geller-Seifter conflict test in rats: Analysis of individual variability. Pharmaco. Biochem. Behav. 17:1982;43-48.
9. Baron, J. C. and Abadie, P. S., In vivo study of central-type benzodiazepine receptors in humans by means of positron emission tomography. In Anxiety: Neurobiology, clinic and therapeutic perspectives. M. Hamon, H. Ollat and M. H. Thiébot, ed. Libbey Eurotext, London, 1993, 129-139.
10. Beinfeld, M. C. S., Cholecystrojinin and gastrin chemistry, distribution, release, and activity. In Peptide hormones: effects and mechanisms of action. A. Negro-Vilan and P. M. Conn, ed. CRC Press, Boca Raton, 1988, pp. 41-77.
11. Belzung, C., Le Pape, G., Comparison of different behavioral test situations used in psychopharmacology for measurement of anxiety. Physiol. Behav. 56:1994;623-628.
12. Belzung C., Misslin R., Vogel E., Dodd R. H., Chapouthier G. Anxiogenic effects of methyl-ß-carboline-3-carboxylate in a light/dark choice situation. Pharmacol. Biochem. Behav. 28:1987;29-33.
13. B antagonist, reduces "state", but not "trait" anxiety in mice. Pharmacol. Biochem. Behav. 49:1994;433-436.
14. Bennett D. A., Bernard P. S., Amrick C. L., Wilson D. E., Liebman J. M., Hutchinson A. J. Behavioral, pharmacological profile of CGS 19755, a competitive antagonist at N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 250:1989;454-460.
15. Beuzen A., Belzung C. Link between emotional memory and anxiety states: A study by principal component analysis. Physiol. Behav. 58:1995;111-118.
16. 1B receptors in the rat brain. Eur. J. Pharmacol. 294:1996;531-540.
17. Boulenger J. P., Boyer P. Mixed anxiety and depression: Clinical issues. Eur. Psychiat. 9:1994;219-226.
18. Bradwejn J., de montigny C. Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurons. Nature. 312:1984;363-364.
19. 4-panic in panic disorder. Clin. Pharmacol. 15:1992;1-5.
20. Bradwejn J., Koszycki D., Meterissian G. Cholecystokinin-tetrapeptide induced panic attacks in panic disorder. Can. J. Psychiatr. 35:1990;83-85.
21. Bradwejn, J., Koszycki, D. and Payeur, R. S., Chaecystokinin-terrapeptide: a provocation agent for research in panic disorders? In New concepts in anxiety. M. Briley and S. E. File, ed. The MacMillan press, London, 1991, pp. 313-319.
22. Braestrup C., Nielsen M., Olsen C. Urinary and brain ß-carboline-3-carboxylate as potent inhibitors of brain benzodiazepine receptors. Proc. Natl. Acad. Sci. USA. 77:1980;2288-2292.
23. Brain P. F., Kusumorini N., Benton D. Anxiety in laboratory rodents - a brief review of some recent behavioural developments. Behav. Process. 25:1991;71-80.
24. Briley, M. and Chopin, P. S., Serotonin in anxiety. Evidence from animal models. In 5-hydroxytryptamine in psychiatry: A spectrum of ideas. M. Sandler, A. Coppen and S. Harnett, ed. Oxford University Press, Oxford, 1991, pp. 177-197.
25. Brown, J., Lewis, V., Brown, M., Horn, G., Bowes, J. B., A comparison between transient amnesias induced by two drugs (diazepam and lorazepam) and amnesia of organic origin. Neuropsychologia. 20:1982;55-70.
26. Chapouthier G., Venault P., Prado de Carvalho L., Simiand J., Rossier J. Possible effects of ß-carbolines on memory. Soc. Neurosci. Abst. 10:1984;647.
27. Charney, D. S., Heninger, G. R., Breier, A., Noradrenergic function in panic anxiety; effects of yohimbine in healthy subjects and patients with agoraphobiea and panic disorder. Arch. Gen. Psychiatry. 41:1984;751-776.
28. Chopin P., Briley M. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology (Berlin). 110:1993;409-414.
29. Clarke A., File S. E. Effects of ACTH, benzodiazepines and 5-HT antagonists on escape from periaqueductal grey stimulation in the rat. Biol. Psychiat. 6:1982;27-35.
30. A receptor: Involvement in behavioral pathogenesis. J. Physiol. (Paris). 90:1996;1-13.
31. Clément Y., Adelbrecht C., Martin B., Chapouthier G. Association of autosomal loci with the grooming activity observed in open-field in mice. Life Sci. 55:1994;1725-1734.
32. Clément Y., Bondoux D., Launay J. M., Chapouthier G. Convulsive effects of a benzodiazepine receptor inverse agonist: Are they related with anxiogenic processes? J. Physiol. (Paris). 91:1997;21-29.
33. Clément Y., Kia H. K., Daval G., Vergé D. An autoradiographic study of serotonergic receptors in a murin genetic model of anxiety related-behaviors. Brain Res. 709:1996;229-242.
34. Clément Y., Martin B., Venault P., Chapouthier G. Involvement of regions 4th and 7th chromosomes in the open-field activity in mice. Behav. Br. Res. 70:1995;51-57.
35. Clément Y., Proeschel M. F., Bondoux D., Girard F., Launay J. M., Chapouthier G. Genetic factors regulate processes related to anxiety in mice. Brain Res. 752:1997;127-135.
36. Cole B. J., Hillmann M., Seidelmann D., Klewer M., Jones G. H. Effects of benzodiazepine receptor partial inverse agonists in the elevate plus-maze test of anxiety in the rat. Psychopharmacology (Berlin). 121:1995;118-126.
37. Cole J. C., Burroughs G. J., Laverty C. R., Sheriff N. C., Sparham E. A., Rodgers R. J. Anxiolytic-like effects of yohimbine in the murine plus-maze: Strain independence and evidence against a2-adrenoreceptor mediation. Psychopharmacology (Berlin). 118:1995;425-436.
38. Corda M. G., Blacker W. D., Mendelson W. B., Guidotti A., Costa E. Beta-carbolines enhance shock induced suppression of drinking in rats. Proc. Natl. Acad. Sci. USA. 80:1983;2072-2076.
39. Corda M. G., Ferrari M., Guidotti A., Konkel D., Costa E. Isolation, purification and partial sequence of a neuropeptide (diazepam-binding inhibitor) precursor of an anxiogenic putative ligand for benzodiazepine recognition site. Neurosci. Lett. 47:1984;319-324.
40. Costall B., Jones B. J., Kelly M. E., Naylor R. J., Tomkins D. M. Exploration of mice in a black and white test box: Validation as a model of anxiety. Pharmacol. Biochem. Behav. 32:1989;777-785.
41. Crawley J. N. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol. Biochem. Behav. 15:1981;695-699.
42. Crawley J. N. Comparative distribution of cholecystokinin and other neuropeptides. Ann. NY Acad. Sci. 448:1985;1-8.
43. Crawley, J. N., Schneidt, W. M., Contrera, J.-F., Does social environment decrease propensity to fight in male mice? Behav. Biol. 15:1975;763-783.
44. Croucher M. J., Collins J. F., Meldrum B. S. Anticonvulsant action of exitatory amino acids antagonists. Science. 216:1982;899-901.
45. Curran, V., Tranquillising memories: A review of the effects of benzodiazepines on human memory. Biol. Psychol. 23:1986;179-213.
46. Curtis, D. R., Duggan, A. W., Johnston, G. A. R., The specificity of strychnine as a glycine antagonist in the mammalian spinal cord. Exp. Brain Res. 12:1987;547-565.
47. Curzon, G., Gibson, E. L., Kennedy, A. J., Kennett, G. A., Sarma, G. S. and Whitton, P. S., In Anxiogenic and other effects of MCCP, a 5-HT1C agonist. New concepts in anxiety. M. Briley and S. E. File, ed. The MacMillan Press, London, 1991, pp. 154-168.
48. Darmani N. S., Martin B. R., Pandey U., Glennon R. A. Pharmacological characterization of ear-scratch response in mice as a behavioral model for selective 5HT2 receptor agonists and evidence for 5HT1b and 5HT2 receptor interactions. Pharmacol. Biochem. Behav. 37:1990;95-99.
49. Daugé, V., Ladurelle, N., Derrien, M., Durieux, C. and Roques, B. P. S., Potential therapeutic applications of CCK antagonists in anxiety and panic disorders. In Anxiety: Neurobiology, clinic and therapeutic perspectives. M. Hamon, H. Ollat and M. Thiébot, ed. Libbey Eurotext, London, 1993, pp. 167-176.
50. Davies C., Steinberg H. A biphasic effect of chlordiazepoxide on animal locomotor activity. Neurosci. Lett. 46:1984;347-351.
51. Davis M., Rainnie D., Cassell M. Neurotransmission in the rat amygdala related to fear and anxiety. T.I.N. 17:1994;208-214.
52. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch. Gen. Psychiat. 46:1989;511-517.
53. de Robertis E., Penà C., Paladini A. C., Medina J. H. New developments on the search for the endogenous ligand(s) of central benzodiazepine receptors. Neurochem. Int. 13:1988;1-11.
54. 1A receptor agonists: Recent developments and controversial issues. Psychopharmacology. 121:1995;1-26.
55. Dishman R. K., Dunn A. L., Youngstedt S. D., Davis J. M., Burgess M. L., Wilson S. P.et al. Increased open-field locomotion and decreased striatal GABA(A) binding after activity wheel running. Physiol. Behav. 60:1996;699-705.
56. Dooley D. J., Klamt I. Differential profile of the CCKB recptor antagonsit CI 988 and diazepam in the four-plate test. Psychopharmacology (Berlin). 112:1993;452-454.
57. Dorow, R., Horowski, R., Paschelke, G., Amin, M., Braestrup, C., Severe anxiety induced by FG 7142, a ß-carboline ligand for benzodiazepine receptors. Lancet. 9:1983;98-99.
58. Diagnostic and Statistical Manual of Mental Disorders (DSM IV). American Psychiatric Association, Washington, DC, 1994, p. 886.
59. Duka T., Ackenheil M., Noderer J., Doenicke A., Dorow R. Changes in noradrenaline plasma levels and behavioral responses induced by benzodiazepine agonists with the benzodiazepine antagonist Ro 15-1788. Psychopharmacology. 90:1986;351-357.
60. Early, C. J., Leonard, B. E., The effect of testosterone and cyprosterone acetate on the concentration of gamma-aminobutyric acid in brain areas of aggressive and nonaggressive mice. Pharmacol. Biochem. Behav. 6:1977;409-413.
61. 4 receptors. TIPS. 16:1995;391-398.
62. Essman, W. B., Benzodiazepines and aggressive behavior. Mod. Probl. Pharmacopsychiatry. 13:1978;13-28.
63. File S. E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods. 2:1980;219-238.
64. File, S. E., Lister, R. G., Nutt, D. J., The anxiogenic action of benzodiazepine antagonists. Neuropharmacology. 21:1982;1033-1037.
65. Flint J., Corley R., De Fries J. C., Fulker D. W., Gray J. A., Miller S.et al. A simple genetic basis for a complex psychological trait in laboratory mice. Science. 269:1995;1432-1435.
66. Garattini, S. S., The Benzodiazepines. Raven Press, New York, 1973.
67. Geller, I., Seifter, J., The effects of meprobamate, barbiturate, d-amphetamine and promazine on experimentally-induced conflict in the rat. Psychopharmacologia. 1:1960;482-492.
68. Ghoneim, M. M., Hinrichs, J. V., Mewaldt, S. P., Dose-response analysis of the behavioral effects of diazepam: I - Learning and memory. Psychopharmacology. 44:1984;291-295.
69. Ghoneim, M. M., Mewaldt, S. P., Effects of diazepam and scopolamine on storage, retrieval and organizational processes in memory. Psychopharmacology. 44:1975;257-262.
70. Ghoneim M. M., Mewaldt S. P. Benzodiazepines and human memory: A review. Anesthesiology. 72:1990;926-938.
71. Graeff F. G., Guimares F. S., de Andrade T. G., Deakin J. F. Role of 5-Ht in stress, anxiety and depression. Pharmacol. Biochem. Behav. 54:1996;129-141.
72. Graeff F. G., Silveira M. C., Nogeira R. L., Audi E. A., Oliveira R. M. Role of the amygdala and periacqueductal gray in anxiety and panic. Behav. Brain Res. 58:1993;123-131.
73. Griebel G. 5-hydroxytryptamine pathways in anxiety and its treatment. Pharmacol. Ther. 66:1995;103-148.
74. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research. Pharmacol. Ther. 65:1995;319-395.
75. Griebel G., Moreau J. L., Jenck F., Misslin R., Martin J. R. Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology (Berlin). 113:1994;463-470.
76. Guillot, P. V., Chapouthier, G., Intermale aggression and dark/light preference in ten inbred mouse strains. Behav. Brain Res. 77:1996;211-213.
77. Guy, A. P., Gardner, C. R., Pharmacological characterisation of a modified social interaction model of anxiety in the rat. Neuropsychobiol. 13:1985;194-200.
78. Hamon M. Neuropharmacology of anxiety: Perspectives and prospects. Trends Pharmacol. Sci. 15:1994;36-39.
79. Hamon, M., Ollat, H. and Thiébot, M.-H., Anxiety: Neurobiology, Clinic and Therapeutic Perspectives. Libbey Eurotext and Editions, Paris, 1993, p. 212.
80. Hata T., Itoh E., Nishikawa H. Behavioral characteristics of SART-stressed mice in the forced swim test and drug action. Pharmacol. Biochem. Behav. 51:1995;849-853.
81. Hayashi, S., The effect of cage-mates on aggression in male mice. Zool. Sci. 8:1991;915-918.
82. Higgit A., Lader M., Fonagy P. The effects of the benzodiazepine antagonist RO 15-1788 on psychophysiological performance and subjective measures in normal subjects. Psychopharmacology. 89:1986;395-403.
83. Hogg S. A review of the validity and variability of the elevated plus-maze as an animpal model of anxiety. Pharmacol. Biochem. Behav. 54:1996;21-30.
84. Hoyer D., Clarke D. E., Fozard J. R., Hartig P. R., Martin G. R., Mylecharane E. J.et al. VII. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46:1994;157-203.
85. 125I]iodocyanolopindolol. Eur. J. Pharmacol. 118:1985;1-12.
86. Hughes J., Bodeen P., Costall B., Domeney A., Kelly E., Horwel D. C.et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA. 87:1990;6728-6732.
87. Hunkeler W., Möhler H., Pieri L., Polc P., Bonetti E. P., Cumin R.et al. Selective antagonists of benzodiazepines. Nature. 290:1981;514-516.
88. Huppert, F. A., Iversen, S. D., Response suppression in rats: A comparison of response-contingent and noncontingent punishment and the effects of the minor tranquilizer, chlordiazepoxide. Psychopharmacologia. 4:1975;67-75.
89. Imai K., Kingsley D. M. Mouse chromosome 9. Mamm. genome. 5:1994;S139-153.
90. Inoue O., Akimoto Y., Mashimoto K., Yamasaki T. Alterations in biodistribution of 3H Ro 151788 in mice by acute stress: Possibly changes in in vivo binding availability to brain benzodiazepine receptor. Int. J. Nucl. Med. Biol. 12:1985;369-374.
91. 3 receptors. Psychopharmacology. 97:1989;489-495.
92. Jessa M., Nazar M., Bidinski A., Plaznik A. The effects of repeated administration of diazepam, MK 801 and CGP 37849 on rat behavior in two models of anxiety. Eur. Psychopharmacol. 6:1996;55-61.
93. Johnston A. L., The implication of noradrenaline in anxiety. In New concepts in anxiety. In M. Briley M. and S. E. File, ed. The MacMillan Press, London, 1991, pp. 347-365.
94. 1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat? J. Pharm. Exp. Ther. 272:1995;920-929.
95. Jones G. H., Schneider C., Seidler J., Cole B. J., Stephens D. N. Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: An analysis based on the fractional receptor occupancies. Psychopharmacology (Berlin). 114:1994;191-199.
96. Karcz-Kubicha M., Liljequist S. Evidence for an anxiogenic action of AMPA receptor antagonists in the plus-maze test. Eur. J. Pharmacol. 279:1995;171-177.
97. Kilts, C. D., Commissaris, R. L., Rech, R. H., Comparison of anti-conflict drug effects in three experimental animal models of anxiety. Psychopharmacology. 74:1981;290-296.
98. Lal H., Kumar B., Forster M. J. Enhancement of learning and memory in mice by a benzodiazepine antagonist. FASEB. 2:1988;2707-2711.
99. Lamberty Y., Gower A. J. Arm width and brightness modulation of spontaneous behavior of two strain of mice tested in the elevated plus-maze. Physiol. Behav. 59:1996;439-444.
100. 3H] zacopride as radioloigands. Synapse. 10:1992;271-281.
101. Lister R. G. The amnesic action of benzodiazepines in man. Neurosci. Biol. Behav. Rev. 9:1985;87-94.
102. Lister, R. G., The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
103. Lister, R. G., File, S. E., The nature of lorazepam-induced amnesia. Psychopharmacology. 83:1984;183-187.
104. Lopez-Rubalcava C., Saldivar A., Fernandezguasti A. Interaction of GABA and serotonin in the anxiolytic action of diazepam and serotonergic anxiolytics. Pharmacol. Biochem. Behav. 43:1992;433-440.
105. Lorenz, K., Der Kumpan in der Umwelt des Vogels, die Artgenosse als auslösendes Moment socialer Verhaltungsweisen. J. Ornith. 83:1935;137-213.
106. Lorenz K., Evolution and Modification of Behaviour. Chicago University Press, Chicago, IL, 1965.
107. Mac Cloy, R. F., Reversal of conscious sedation by flumazenil: Current status and future prospects. Acta Anaesthesiol. Scandinav., 1995, 35-42.
108. Mac Ginty-Weisker S., Barkeley M. Female genotype influences the behavioral performance of mice selected for reproductive traits. Physiol. Behav. 50:1991;807-813.
109. A receptors and anxiety: From neurobiology to treatment. G. Biggio, E. Sanna and E. Costa, ed. Raven Press, New York, 1995, pp. 115-133.
110. Mandel, P., Mack, G. and Kempf, E. S., Molecular basis of some models of aggressive beahvior. In Psychopharmcology of aggression. M. Sandler, ed. Raven Press, New York, 1979, pp. 95-110.
111. 3 receptor, a serotonin-gated ion channel. Science. 254:1991;432-437.
112. Mathis C., Neumann P. E., Gershenfeld H., Paul S. M., Crawley J. N. Genetic analysis of anxiety-related behaviors and response to benzodiazepine-related drugs in AXB and BXA recombinant inbred mouse strains. Behav. Genet. 25:1995;557-568.
113. Matsuo M., Kataoka Y., Mataki S., Kato Y., Oi K. Conflict situation increases serotonin release in rat dorsal hippocampus - in vivo study with microdialysis and Vogel test. Neurosci. Lett. 215:1996;197-200.
114. Mayo W., Dellu F., Cherkaoui J., Chapouthier G., Dodd R. H., Le Moal M.et al. Cognitive enhancing properties of ß-ccm infused into the nucleus basalis magnocellularis of the rat. Brain Res. 589:1992;109-114.
115. Medina J. H., Novas M. L., De Robertis E. Change in benzodiazepine receptors by acute stress: Different effect of diazepam or Ro 151788 treatment. Eur. J. Pharmacol. 96:1983;181-185.
116. Miczek K. A., Weerts E. M., Vivian J. A., Barros H. M. Aggression, anxiety and vocalizations in animals: GABA A and 5-HT anxiolytics. Psychopharmacology. 121:1995;38-56.
117. Miller L. G., Thompson M. L., Greenblatt D. J., Deutsch S. I., Shader R. I., Paul S. M. Rapid increase in brain benzodiazepine receptor binding following defeat stress in mice. Brain Res. 414:1987;395-400.
118. Mohanan, E., Maxson, S. C., Chemosignal dependent and independent effects of Y chromosomal gene(s) on offense in mice. Behav. Genet. 20:1990;735-745.
119. Möhler H., Polc P., Cumin R., Pieri L., Kettler R. Nicotinamide is a brain constituant with benzodiazepine-like actions. Nature. 278:1979;563-565.
120. Nadeau J. H., Davisson M. T., Doolittle D. P., Grant P., Hillyard A. L., Kosowsky M. R.et al. Comparative map for mice and humans. Mamm Genome. 3:1992;480-536.
121. Nashold B. S. J., Wilson N. P., Slaughter G. S. Sensations evoked by stimulation in the midbrain of man. J. Neurosurg. 30:1969;14-24.
122. Ninan, P. T., Ninan, T. M. I., Cohen, R. M., Cook, J. M., Skolnick, P., Paul, S. M., Benzodiazepine receptor-mediated experimental "anxiety" in primates. Science. 218:1982;1332-1334.
123. Pazos A., Cortès R., Palacios J. M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II Serotonin-2 receptors. Brain. Res. 346:1985;231-249.
124. Pazos A., Palacios J. M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I Serotonin-1 receptors. Brain Res. 346:1985;205-230.
125. Peeler D. F., Nowakowsky R. S. Genetic factors and the measurement of exploratory activity. Behav. Neural Biol. 48:1987;90-103.
126. Pellow S., Chopin P., File S., Briley M. Validation of open:closed arm entries in an elevated plus maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14:1985;149-167.
127. Pellow, S., File, S. E., Multiple site of action for anxiogenic drugs: Behavioural, electrophysiological and biochemical correlations. Psychopharmacology. 83:1984;304-315.
128. Peroutka S. Molecular biology of serotonin (5-HT) receptors. Synapse. 18:1994;241-260.
129. Petersen E. N., Jensen L. H. Proconflict effect of benzodiazepine inverse agonists and other inhibitors of GABA function. J. Pharmacol. 103:1984;91-97.
130. Pigott T. A. OCD: Where the serotonin selectivity story begins. J. Clin. Psy. 57:1996;11-20.
131. Plomin R., McClear G. E., Gora-Maslak G., Neiderhiser J. M. Use of Recombinant Inbred Strains to detect quantitative trait loci associated with behavior. Behav. Genet. 21:1991;99-116.
132. Pope, H. G., Hudson, J. L., Jonas, J. M., Yugerlun-Tood, D., Antidepressant treatment of bulimia: A two-year follow-up study. J. Clin. Psychopharm. 5:1985;320-327.
133. Prado de Carvalho L., Grecksch G., Cavalheiro E. A., Dodd R. H., Chapouthier G., Rossier J. Characterization of convulsions induced by methyl ß-carboline-3-carboxylate in mice. Eur. J. Pharmacol. 103:1984;287-293.
134. Prado de Carvalho L., Grecksch G., Chapouthier G., Rossier J. Anxiogenic and non-anxiogenic benzodiazepine antagonists. Nature. 301:1983;64-66.
135. 1A agonists disrupt memory of fear conditionning in mice. Biol. Psychiat. 3:1993;347-354.
136. Raffalli-Sébille M.-J., Chapouthier G. Flumazenil (Ro 15-1788) enhances learning in both negatively and positively reinforced tasks. Drug Dev. Res. 23:1991;153-157.
137. Raffalli-Sébille M.-J., Chapouthier G. Similar effects of a ß-carboline and of flumazenil in negatively and positively reinforced learning tasks in mice. Life Sci. 48:1991;685-692.
138. Raffalli-Sébille M.-J., Venault P., Dodd R. H., Chapouthier G. Methyl ß-carboline-3-carboxylate enhances performances in a multiple-trial learning task in mice. Pharmacol. Biochem. Behav. 35:1990;281-284.
139. Ravard S., Dourish C. T. Cholecystokinin and anxiety. TIPS. 11:1990;271-273.
140. Rex A., Sondern U., Voigt J. P., Franck S., Fink H. Strain differences in fear-motivated behavior of rats. Pharmacol. Biochem. Behav. 54:1996;107-111.
141. 1A receptor antagonist, in the murine elevated plus-maze test. Eur. J. Pharmacol. 261:1994;321-325.
142. Rodgers R. J., Cole J. C., Cobain M. R., Daly P., Doran P. J., Eells J. R.et al. Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: Profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav. Pharmac. 3:1992;621-634.
143. Samson Y., Hat P., Baron J. C., Soussaline F., Comar D., Mazière M. Kinetics and displacement of 11C RO 15-1788, a benzodiazepine antagonist studied in human brain in vivo by positron emision tomography. Eur. J. Pharmacol. 110:1985;247-251.
144. Sanchez C., Arnt J., Hyttel J., Moltzen E. K. The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice. Psychopharmacology. 110:1993;53-59.
145. Sangameswaran L., Fales H. M., Friedrich P., de Blas A. L. Purification of a benzodiazepine from bovine brain and detection of benzodiazepine-like immunoreactivity in human brain. Proc. Natl. Acad. Sci. USA. 83:1986;9236-9240.
146. Sanger D. J., Animal models of anxiety and the screening and development of novel anxiolytic drugs. In Animal models in psychiatry, II. A. Boulton, G. Baker and M. Martin-Iverson, ed. The Humana Press, New York, 1991, pp. 147-198.
147. 1B receptor. Science. 265:1994;1875-1878.
148. Schneider L. S. Overview of generalized anxiety disorder in the elderly. J. Clin. Psychiat. 57:1996;34-45.
149. Sepinwall, J. and Cook, L. S., Behavioral pharmacology of antianxiety drugs. In Handbook of psychopharmacology. L. L. I. S. D. Iversen, S. D. Snyder, ed. Plenum Press, New York, 1978, pp. 345-393.
150. Shimada T., Matsumoto K., Osanai M., Matsuda H., Terasawa K., Watanabe H. The modified light/dark transition test in mice: Evaluation of classic and putative anxiolytic and anxiogenic drugs. Gen. Pharmacol. 26:1995;205-210.
151. Siegfried, B., Alleva, E., Oliverio, A., Puglisi-Allegra, S., Effect of isolation on activity, reactivity, excitability and aggressive behavior in two inbred strains of mice. Behav. Brain Res. 2:1981;211-218.
152. Simler, S., Puglisi-Allegra, S., Mandel, P., Gamma aminobutyric acid in brain areas of isolated aggressive and non-aggresssive inbred strains of mice. Pharmacol. Biochem. Behav. 16:1982;57-61.
153. Simon P., Panissaud C., Costentin J. Anxiogenic-like effects induced by stimulation of dopamine receptors. Pharmacol. Biochem. Behav. 45:1993;685-690.
154. Simon P., Panissaud C., Costentin J. The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice. Psychopharmacology. 114:1994;597-600.
155. Singh L., Lewis A. S., Field M. J., Hughes J., Woodruff G. N. Evidence for an involvement of the brain cholecystokinin-B receptor in anxiety. Proc. Natl. Acad. Sci. USA. 88:1991;1130-1133.
156. Sleight, A. J., Pierce, P. A., Schmidt, A. W., Hekmatpanah, C. R. and Peroutka, S. J. S. The clinical utility of serotonin receptor active agents in neuropsychiatric disease. In Serotonin receptor subtypes: basic and clinical aspects. S. J. Peroutka, ed. Wiley, New York, 1991, pp. 211-227.
157. Soubrié, P., Simon, P., Boissier, J. R., Amnésie induite chez le rat par les benzodiazépines lors d'une situation ne faisant pas intervenir de composante nociceptive. C. R. Acad. Sci. Paris (D). 283:1976;203-205.
158. Spruijt B. M., Van Hooff J. A. R. A. M., Gispen W. H. Ethology and neurobiology of grooming behavior. Physiol. Rev. 72:1992;825-852.
159. Squires R. F., Braestrup C. Benzodiazepine receptors in rat brain. Nature. 266:1977;732-734.
160. Stefanski R., Palejko W., Kostowski W., Plaznik A. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in 2 animal models of anxiety. Neuropharmacology. 31:1992;1251-1258.
161. Stoudemire A. Epidemiology and psychopharmacology of anxiety in medical patients. J. Clin. Psychiat. 57:1996;64-72.
162. Streng J. Open-field behavior in four inbred mouse strains. Can. J. Psychol. 25:1971;62-68.
163. Tallman J. F., Paul S. M., Skolnick P., Gallager D. W. Receptors for the age of anxiety: Pharmacology of the benzodiazepines. Science. 207:1980;274-281.
164. Thiébot, M.-H. S. Current behavioral models of anxiety in animals: how predictive are they for anxiolytic activity? In Anxiety: Neurobiology, clinic and therapeuthic perspectives. M. Hamon, H. Ollat and M.-H. Thiébot, ed. Libbey Eurotext, London, 1993, pp. 25-37.
165. Thiébot, M.-H., Le Bihan, C., Soubrié, P., Simon, P., Benzodiazepines reduce the tolerance to reward delay in rats. Psychopharmacology. 86:1985;147-152.
166. Thiébot, M.-H. and Martin, P.S. Effects of benzodiazepines 5-HT1A agonists and 5-HT3 antagonists in animal models sensitive to antidepressant drugs. In 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines: Their comparative behavioural pharmacology. R. J. C. S. J. Rodgers and C. S. J. Rodgers, ed. Wiley, Chichester, 1991, pp. 159-194.
167. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 44:1993;463-469.
168. Turski L., Schwarz M., Turski W. A., Klockgether T., Sontag K. H., Collins J. F. Muscle relaxant action of exitatory amino acid antagonists. Neurosci. Lett. 53:1985;321-326.
169. Vasar E., Peuranen E., ÖÖpik T., Harro J., Männistö P. T. Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze. Psychopharmacology. 110:1993;213-218.
170. Venault, P., Effets comportementaux de trois ligands du complexe récepteur GABA-Benzodiazépines. Thèse de Doctorat de l"Université Paris Sud, 1987.
171. Venault P., Chapouthier G., Prado de Carvalho L., Rossier J. Effects of convulsant ligands of the GABA-benzodiazepine receptor in conflict and learning tasks in mice. L'Encéphale. 18:1992;655-660.
172. Venault, P., Prado de Carvalho, L., Rossier, J. and Chapouthier, G. S., Anxiogenic and memory enhancing effects of drugs acting at the GABA-benzodiazepine receptor complex. In Learning and memory - mechanism of information storage in the nervous system. H. J. Matthies, ed. Pergamon Press, Oxford, 1986, pp. 387-390.
173. 1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J. Neurosci. 6:1986;3474-3482.
174. Vogel, J. R., Beer, B., Clody, D. E., A simple and reliable conflict procedure for testing antianxiety agents. Psychopharmacologia. 21:1971;1-7.
175. Walsh R. N., Cummins R. A. The open-field test: A critical review. Psychol. Bull. 83:1976;482-504.
176. Wettstein J. G., Bueno L., Junien J. L. CCK antagonists: Pharmacology and therapeutic interest. Pharmacol. Ther. 62:1994;267-282.
177. Wiley, J. L. and Balster, R. L. S., Preclinical evaluation of N-methyl-D-aspartate antagonists for antianxiety effects: a review. In Multiple sigma and PCP receptor ligands: Mechanisms for neuromodulation and neuroprotection? J. M. Kamenka and E. F. Domino, ed. NPP Books, Ann Arbor, 1992, pp. 801-815.
178. Woodruf G. N., Hugues J. Cholecystokinin antagonists. Ann. Rev. Pharmacol. Toxicol. 31:1991;469-501.